August 29, 2026NEJM Evidence
A Hat Trick for RSV Vaccines — Prevention of Disease, Hospitalization, and Beyond
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Together, these data provide real-world evidence to support RSV vaccination, while highlighting the need to better define re-vaccination schedules.”
“In this large-scale, pragmatic, phase 4 trial, the RSVpreF vaccine as compared with no vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease, as well as the incidence of hospitalization for respiratory tract disease from any cause, among adults 60 years of age or older.”
“Vaccines remain one of the greatest public health achievements, and large-scale evaluations such as this one have the power to reveal benefits that extend beyond prevention of the target infection. Recognizing these broader impacts underscores that...”
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Chu et al. (2026) studied this question.